Biohaven has concluded enrolment in the pivotal RISE3 Phase II/III trial assessing the selective Kv7.2/7.3 channel activator, ...
Morning Overview on MSN
A single gene-editing infusion cut severe swelling attacks by 87 percent in a trial
People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...
Clinical trials are designed not just to test whether a treatment works, but to do so in a way that eliminates bias. Two common trial designs—open-label and double-blind—differ sharply in this ...
The double-blind, randomised, multicentre, placebo-controlled study aims to enrol around 468 patients.
Impact of Trastuzumab on Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancers: A Real-World Analysis From a High-Incidence Region (REAL TAB) Eligible patients ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase ...
Dupilumab significantly outperformed omalizumab in reducing the size of nasal polyps and improving sense of smell in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting ...
Patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA) are at risk for recurrent stroke. Low factor XI levels are associated with a reduced risk of ischemic stroke.
The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results